Tag: weight

  • People coming off weight-loss injections risk fast weight gain | Stopping weight-loss jabs leads …

    People coming off weight-loss injections risk fast weight gain | Stopping weight-loss jabs leads …

    Explore the latest developments concerning People coming off.

    People coming off weight-loss injections risk fast weight gain

    Slimmers who come off weight-loss injections such as Mounjaro or Wegovy can regain their lost pounds four times faster than those who stop conventional dieting and exercising, new research suggests.

    Data published in the British Medical Journal suggests overweight people shed large amounts when using jabs – about a fifth of their body weight – but once they quit they regain 0.8 kg every month, on average.

    That means they return to their pre-treatment weight in a year and a half.

    "People buying these need to be aware of the risk of fast weight regain when the treatment ends," warns investigator Dr Susan Jebb, from Oxford University.

    Stopping weight-loss jabs leads to much faster rebound than thought – so are they still worth it?

    Sam West receives funding from the National Institute of Health Research and is a co-investigator on three weight loss trials funded by the Novo Nordisk Foundation.

    Dimitrios Koutoukidis receives funding from the National Institute of Health Research and is principal investigator in publicly-funded investigator-led research studies where Oviva and Nestle Health Sciences have contributed to the costs or delivery of weight-loss interventions. He supervised an iCASE PhD studentship where Second Nature was an industry partner.

    Susan Jebb receives research grant funding from National Institute of Health Research and is principal investigator in a research programme funded by the Novo Nordisk Foundation

    Oviva, Second Nature, Nestle Health Sciences have contributed to the costs or delivery of weight-loss interventions as part of some of research studies funded by the National Institute of Health Research.

    ICY DBS blyth doll 1/6 bjd toy joint body white skin shiny & matte face 30cm on sale special price toy gift anime doll

    ICY DBS blyth doll 1/6 bjd toy joint body white skin shiny & matte face 30cm on sale special price toy gift anime doll
    Limited time offer! »

    The dynamic landscape of current events often brings forth significant discussions. Monitoring these developments provides crucial insights.

    For more detailed information, explore updates concerning People coming off.

    For more news…

  • Weight loss drug recommended for PBS | newsGP – Wegovy recommended for PBS listing | Aussies with…

    Weight loss drug recommended for PBS | newsGP – Wegovy recommended for PBS listing | Aussies with…

    Explore the latest developments concerning Weight loss drug.

    newsGP – Wegovy recommended for PBS listing

    The PBAC recommended it be listed for adults with established cardiovascular disease with obesity, while also identifying which groups could have more affordable access to GLP-1s.

    Semaglutide (sold as Wegovy) is now a significant step closer to being added to the Pharmaceutical Benefits Scheme (PBS) for adults with established cardiovascular disease with obesity.
     
    It comes after the Pharmaceutical Benefits Advisory Committee (PBAC) recommended the listing at its November meeting, releasing its decision late on Friday.
     
    ‘Patients must have already experienced a cardiovascular event such as a heart attack, stroke, or have symptomatic peripheral arterial disease,’ PBAC said.
     
    ‘To best reach patients at high risk and considering the high cost of treatment, the PBAC determined it would be appropriate to limit PBS access to people with a BMI of 35 kg/m² or higher, or 32.5 kg/m² or higher for people of Asian, Aboriginal, or Torres Strait Islander ethnicity.’
     
    The cost barrier to some Australians accessing weight-loss drugs more broadly could also soon be lifted following new PBAC advice to the health minister.
     
    At the request of Federal Health and Ageing Minister Mark Butler, the PBAC undertook a comprehensive review of glucagon-like peptide-1 (GLP-1) receptor agonist medicines for obesity, focussing on equitable access.
     
    The PBAC has now released its recommendation on which groups should be prioritised to ensure ‘equitable subsidised access to GLP-1 for the treatment of obesity’.
     
    ‘Based on current evidence’, the PBAC considered this should include:

    Pink Lace Front Wig Human Hair For Women 13×4 Hd Lace Frontal Wig Brazilian 613 13×6 Colored Straight Lace Front Wigs

    Pink Lace Front Wig Human Hair For Women 13x4 Hd Lace Frontal Wig Brazilian 613 13x6  Colored Straight Lace Front Wigs
    Click for more info. »

    The dynamic landscape of current events often brings forth significant discussions. Monitoring these developments provides crucial insights.

    For more detailed information, explore updates concerning Weight loss drug.

    For more news…